company background image
UBI

Universal BiosensorsASX:UBI Stock Report

Market Cap

AU$139.6m

7D

3.3%

1Y

161.7%

Updated

16 Oct, 2021

Data

Company Financials
UBI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

UBI Overview

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company in Australia.

Universal Biosensors Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Universal Biosensors
Historical stock prices
Current Share PriceAU$0.79
52 Week HighAU$0.29
52 Week LowAU$0.97
Beta1.12
1 Month Change-12.78%
3 Month Change0%
1 Year Change161.67%
3 Year Change248.89%
5 Year Change134.33%
Change since IPO-21.50%

Recent News & Updates

May 13
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Universal...

Shareholder Returns

UBIAU Medical EquipmentAU Market
7D3.3%-0.7%0.9%
1Y161.7%-4.9%20.2%

Return vs Industry: UBI exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.

Return vs Market: UBI exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is UBI's price volatile compared to industry and market?
UBI volatility
UBI Beta1.12
Industry Beta0.57
Market Beta1

Stable Share Price: UBI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: UBI's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200160John Sharmanhttps://www.universalbiosensors.com

Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It offers SENTIA Wine Analyzer to test Free Sulphur Dioxide; prothrombin time international normalized ratio coagulation test strips; Sentia Free Sulphite test strips; and coagulation testing and calibration services, as well as distributes Siemens’ Xprecia Stride Coagulation Analyzer.

Universal Biosensors Fundamentals Summary

How do Universal Biosensors's earnings and revenue compare to its market cap?
UBI fundamental statistics
Market CapAU$139.57m
Earnings (TTM)-AU$6.33m
Revenue (TTM)AU$5.53m

25.2x

P/S Ratio

-22.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UBI income statement (TTM)
RevenueAU$5.53m
Cost of RevenueAU$3.41m
Gross ProfitAU$2.12m
ExpensesAU$8.44m
Earnings-AU$6.33m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.036
Gross Margin38.31%
Net Profit Margin-114.36%
Debt/Equity Ratio0.2%

How did UBI perform over the long term?

See historical performance and comparison

Valuation

Is Universal Biosensors undervalued compared to its fair value and its price relative to the market?

4.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UBI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UBI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: UBI is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: UBI is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UBI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UBI is good value based on its PB Ratio (4x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Universal Biosensors forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universal Biosensors has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Universal Biosensors performed over the past 5 years?

-13.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UBI is currently unprofitable.

Growing Profit Margin: UBI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UBI is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.

Accelerating Growth: Unable to compare UBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: UBI has a negative Return on Equity (-18.16%), as it is currently unprofitable.


Financial Health

How is Universal Biosensors's financial position?


Financial Position Analysis

Short Term Liabilities: UBI's short term assets (A$28.4M) exceed its short term liabilities (A$7.6M).

Long Term Liabilities: UBI's short term assets (A$28.4M) exceed its long term liabilities (A$7.7M).


Debt to Equity History and Analysis

Debt Level: UBI's debt to equity ratio (0.2%) is considered satisfactory.

Reducing Debt: UBI's debt to equity ratio has reduced from 191.1% to 0.2% over the past 5 years.

Debt Coverage: UBI's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if UBI's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Universal Biosensors's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UBI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

John Sharman (55 yo)

1.75yrs

Tenure

AU$696,392

Compensation

Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, serves as Non-Executive Director at Cann Group Limited since April 27, 2021. He serves as Chief Executive Officer at Universal Biosensors, Inc. since 2020. He...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD516.88K) is above average for companies of similar size in the Australian market ($USD302.45K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Leadership Team

Experienced Management: UBI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: UBI's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Universal Biosensors, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Universal Biosensors, Inc.
  • Ticker: UBI
  • Exchange: ASX
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$139.572m
  • Shares outstanding: 177.80m
  • Website: https://www.universalbiosensors.com

Number of Employees


Location

  • Universal Biosensors, Inc.
  • 1 Corporate Avenue
  • Rowville
  • Victoria
  • 3178
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.